2 completed. 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
Follow Kioga Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) for Stress, Sleep, and Inflammation Mycolicibacterium petrae KGA-10 (heat-killed), Placebo (microcrystalline cellulose) - Stress Resilience, Systemic Inflammation | Not applicable | Completed | Kioga Inc. | 107 | 2025-08-14 | 2026-05-26 |
| Safety and Tolerability of Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) - a Pilot Study Heat-killed Mycolicibacterium petrae KGA-10 (NeuroAlly), Placebo (microcrystalline cellulose) - Safety, Tolerability | Not applicable | Completed | Kioga Inc. | 8 | 2025-07-07 | 2026-06-22 |
Sleep Initiation and Maintenance Disorders (1)
microcrystalline cellulose (2)
United States (2)